^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Neo Vax (NEO-PV-01)

i
Associations
Company:
BioNTech
Drug class:
Immunostimulant
Related drugs:
Associations
Phase 1
Dana-Farber Cancer Institute
Recruiting
Last update posted :
05/27/2024
Initiation :
11/01/2014
Primary completion :
06/01/2025
Completion :
06/01/2026
MGMT
|
MGMT promoter methylation
|
Keytruda (pembrolizumab) • temozolomide • Neo Vax (NEO-PV-01)
Phase 1
Dana-Farber Cancer Institute
Recruiting
Last update posted :
04/23/2024
Initiation :
08/18/2021
Primary completion :
03/31/2026
Completion :
03/31/2028
IGH
|
IGH mutation
|
Keytruda (pembrolizumab) • cyclophosphamide • Neo Vax (NEO-PV-01) • cyclophosphamide intravenous
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
11/16/2021
Initiation :
04/09/2014
Primary completion :
03/28/2016
Completion :
05/18/2018
CTAG1B • CD4 • PRAME
|
CTAG1B expression
|
Hiltonol (poly-ICLC) • Mobista (CDX-301) • Neo Vax (NEO-PV-01) • rasdegafusp alfa (CDX-1401)
Phase 1
BioNTech US Inc.
Completed
Last update posted :
02/25/2021
Initiation :
10/01/2016
Primary completion :
02/01/2019
Completion :
05/01/2020
BRAF
|
Opdivo (nivolumab) • Hiltonol (poly-ICLC) • Neo Vax (NEO-PV-01)
Phase 1
Patrick Ott, MD
Completed
Last update posted :
12/09/2020
Initiation :
01/01/2014
Primary completion :
09/01/2015
Completion :
06/01/2018
IFNA1
|
Hiltonol (poly-ICLC) • Neo Vax (NEO-PV-01)
Phase 1
Washington University School of Medicine
Withdrawn
Last update posted :
04/12/2019
Initiation :
04/30/2019
Primary completion :
06/30/2022
Completion :
05/31/2027
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Hiltonol (poly-ICLC) • Neo Vax (NEO-PV-01)